An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung: A Southwest Oncology Group Study.
D018288:Carcinoma, Small Cell / Q000628:therapy*; D002544:Cerebral Infarction / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003872:Dermatitis / Q000209:etiology; D004317:Doxorubicin / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000209:etiology; D005260:Female; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D011014:Pneumonia / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000209:etiology; D011832:Radiation Injuries / Q000209:etiology*; D011882:Radiotherapy, High-Energy; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide